Eidos Therapeutics Inc. (Palo Alto, Calif.) and Avrobio Inc. (Cambridge, Mass.) proposed NASDAQ IPOs on Friday.
Eidos proposed to raise $115 million in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and Barclays.
Last month, the company raised $64 million in a series B round led by RA Capital (see BioCentury Extra, April 5).
Eidos expects data YE18 from a Phase II evaluating its AG10 to treat transthyretin (TTR) amyloidosis cardiomyopathy. The biotech has rights from Stanford University to the small molecule that binds and stabilizes TTR.
Avrobio proposed to raise $86.3 million in an IPO underwritten by Morgan Stanley, Cowen, Wells Fargo and Wedbush PacGrow.
In February, the company raised $60 million in a series B round led by Cormorant Asset Management and Surveyor Capital (see BioCentury, Feb. 2).
Avrobio is developing a pipeline of CD34+ hematopoietic stem cell therapies that are transduced with lentivirus ex vivo to express therapeutic proteins. Lead candidate AVR-RD-01 -- slated to enter a Phase II trial mid-year -- comprises stem cells engineered to express alpha galactosidase A, the missing enzyme in Fabry’s disease patients.